NCT07914556
Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers
StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Number of participants with dose-limiting toxicities (DLTs)
Timeframe: From the first dose of Cycle 1 through Day 28 of Cycle 1 (each cycle is 28 days)
Number of participants with treatment-emergent adverse events (TEAEs)
Timeframe: From first dose through 28 days after the last dose, an average of 1 year
Secondary (7)
Overall response rate (ORR)
Maximum observed serum concentration (Cmax) of 6MW5311
Area under the serum concentration-time curve (AUC) of 6MW5311
Time to maximum observed serum concentration (Tmax) of 6MW5311
Terminal elimination half-life (t1/2) of 6MW5311
Show 2 moreShow less
Systemic clearance (CL) of 6MW5311
Volume of distribution (V) of 6MW5311
Arms and interventions
Part 1 - Dose Escalation (6MW5311)Experimental
A modified 3+3 design with accelerated titration will be used to evaluate planned dose levels.
Part 2 - Dose Expansion (6MW5311)Experimental
Participants with chronic myelomonocytic leukemia (CMML), multiple myeloma (MM), or relapsed or refractory acute myeloid leukemia (AML; acute myelomonocytic or monocytic subtypes) will receive 6MW5311 at the dose level(s) selected by the Safety Review Committee from Part 1.
Biologicals: 6MW5311
Sites
1 site in 1 country
- Shanghai Jiao Tong University School of Medicine, Ruijin HospitalShanghai, Shanghai Municipality, China